stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Revenue
Haemonetics Corporation's revenue for fiscal 2026 was $1.3B, unchanged from fiscal 2025. Over the twelve months to 30 September 2026 it was $1.4B. Over the past ten years it has ranged from $870.5M (fiscal 2021) to $1.4B (fiscal 2025); the current reading is higher than 92% of that period. Haemonetics Corporation ranks 25th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $1.3B | (1.97%) |
| FY2025 | $1.4B | 3.95% |
| FY2024 | $1.3B | 12.01% |
| FY2023 | $1.2B | 17.67% |
| FY2022 | $993.2M | 14.10% |
| FY2021 | $870.5M | (11.94%) |
| FY2020 | $988.5M | 2.16% |
| FY2019 | $967.6M | 7.04% |
| FY2018 | $903.9M | 2.01% |
| FY2017 | $886.1M | (2.50%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $357.8M | 5.42% |
| Jun 2026 | $339.4M | (2.01%) |
| Mar 2026 | $346.4M | 2.18% |
| Dec 2025 | $339.0M | 3.56% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BRKR Bruker Corporation compare | $3.5B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $2.6B |
| BIO Bio-Rad Laboratories, Inc. compare | $2.6B |
| ITGR Integer Holdings Corporation compare | $1.8B |
| LIVN LivaNova PLC compare | $1.5B |
| HAE Haemonetics Corporation | $1.4B |
| IRTC iRhythm Holdings, Inc. compare | $854.0M |
| TXG 10x Genomics compare | $616.9M |
| AXGN AxoGen, Inc. compare | $266.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on HAE
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement